Innate Pharma SA ( (FR:IPH) ) has provided an announcement.
On April 28, 2025, Innate Pharma S.A. announced the filing of its 2024 Universal Registration Document and Annual Report on Form 20-F. The release included details on the company’s share structure as of April 25, 2025, with 92,175,723 ordinary shares and a total of 92,962,943 theoretical voting rights. This filing is significant for stakeholders as it ensures transparency and compliance with regulatory requirements, potentially impacting investor confidence and market positioning.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company utilizes innovative approaches to harness the innate immune system through three therapeutic strategies: multi-specific NK Cell Engagers via its ANKET® platform, Antibody Drug Conjugates (ADC), and monoclonal antibodies (mAbs). Innate Pharma collaborates with biopharmaceutical companies like Sanofi and AstraZeneca and is headquartered in Marseille, France, with a US office in Rockville, MD. The company is listed on Euronext Paris and Nasdaq.
YTD Price Performance: -50.0%
Average Trading Volume: 1,075
Technical Sentiment Signal: Strong Buy
Current Market Cap: $167.2M
See more data about IPH stock on TipRanks’ Stock Analysis page.